Screening for chronic Q-fever is only cost-effective for specific groups RIVM has investigated for which groups screening for chronic Q-fever might be cost-effective.
Pneumococcal disease in the elderly The Health Council of the Netherlands is preparing an advice on pneumococcal vaccination for the elderly on request of the Ministry of Health, Welfare and Sport.
Statement on health care spending Down syndrome Recently a tweet containing a video from a Dutch tv-show about Down syndrome caused a lot of turmoil on Twitter.
Temporary dermal fillers prove harmless RIVM has conducted a market surveillance study of 26 so-called non-permanent fillers. All 26 products proved to be harmless.
Slight increase of the number of tuberculosis patients in 2016 For the second consecutive year, the number of tuberculosis (TB) patients in the Netherlands increased.
Promising biobased alternatives to controversial polar aprotic solvents There are a number of promising biobased alternatives to controversial polar aprotic solvents, as revealed in a report from Wageningen Food & Biobased Research commissioned by RIVM .
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.
Slight increase of ammonia emissions In 2015 slightly more ammonia was emitted in the Netherlands than in 2014 and the ceiling set by the European Union was met (128 kilotons).
TIME honours Guus Velders of RIVM TIME has named Professor Guus Velders of RIVM as one of the 100 most influential people in the world.
Every year, 300,000 tick bites in urban areas One in 5 tick bites occurs in an urban area. Although most tick bites occur in the countryside, many people are bitten in urban areas as well.